Skip to main content
. 2023 Jul 24;29(8):2068–2078. doi: 10.1038/s41591-023-02469-3

Table 1.

Characteristics of the patients at baseline

Characteristics All patients Well respondersa Poor responders
(n = 25) (n = 11) (n = 14)
Age at enrollment (years)
Mean ± s.d. 65.2 ± 5.3 65.0 ± 6.1 65.3 ± 4.6
Median (range) 65 (55, 75) 65 (55, 75) 65 (57, 72)
Sex (n,%)
Female 3 (12) 2 (18) 1 (7)
Male 22 (88) 9 (82) 13 (93)
Tumor location (n, %)
Proximal third 3 (12) 2 (18) 1 (7)
Middle third 11 (44) 5 (46) 6 (43)
Distal third 11(44) 4 (36) 7 (50)
Clinical disease stageb (n, %)
II 3 (12) 2 (18) 1 (7)
III 20 (80) 8 (73) 12 (86)
IV 2 (8) 1 (9) 1 (7)
Tumor length (x ± s, mm) 40.5 ± 12.7 40.3 ± 12.8 40.6 ± 13.1
Tumor diameter (x ± s, mm) 15.3 ± 4.1 15.3 ± 4.3 15.3 ± 4.2
Smoking status (n, %)
Former/current 10 (40) 6 (55) 4 (29)
Never 15 (60) 5 (45) 10 (71)
PD-L1 statusc (n, %)
CPS > 10 4 (16) 3 (27) 1 (7)
CPS < 10 18 (72) 7 (64) 11 (79)
unknown 3 (12) 1 (9) 2 (14)

a Well responders were defined as having 33% or fewer residual viable tumor cells in the resected tumor. Poor responders were defined as having 33% or more residual viable tumor cells in the resected tumor.

b The clinical disease stage was evaluated according to criteria in the AJCC, eighth edition.

c PD-L1 status was evaluated by CPS using Dako 22C3 antibody.